Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS014 Monotherapy and Combination with Pembrolizumab in Advanced Cancer
NCT05296772Phase 1Recruiting
- Sponsor
- Anwita Biosciences
- Start
- Feb 2022
- Primary completion
- Jun 2024
- Modality
- Nanobodies (VHH), Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of exenokine-21 in solid tumor and lymphoma (2 arms), sponsored by Anwita Biosciences. Primary endpoints: Number of participants with treatment-related adverse events at 24 months, Maximum Tolerated Dose at 24 months and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
exenokine-21
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05296772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296772.